Ishita Drugs & Industries Share Price
73.00+2.12 (+2.99%)
-0.19% past 1 Year
Ishita Drugs & Industries Ltd is the flagship company of the 'Ishita' Group. They are engaged in the manufacture of various Active Pharma Ingredients (bulk actives and their salts) bulk
Corporate filings & documents
Announcements
Company has issued letters providing a weblink of Companys website to access Annual report for Financial Year 2025-26 to those members who have not registered their email addresses.
3 days agoCompany has issued letters providing a weblink of Companys website to access Annual report for Financial Year 2025-26 to those members who have not registered their email addresses.
3 days agoAnnual Report for the Financial Year 2025-26 including Notice of 33rd Annual General Meeting of the Company to be held on 30.09.2026.
1 week agoAnnual Report for the Financial Year 2025-26 including Notice of 33rd Annual General Meeting of the Company to be held on 30.09.2026.
1 week agoNotice of 33RD AGM of the Company which will be held on wednesday 30th September 2026 and E voting period for AGM commence from 27.09.2026 (09:00 a.m. IST) and ends on 29.09.2026 (5:00 p.m. IST)
1 week agoNotice of 33RD AGM of the Company which will be held on wednesday 30th September 2026 and E voting period for AGM commence from 27.09.2026 (09:00 a.m. IST) and ends on 29.09.2026 (5:00 p.m. IST)
1 week agoThe E-voting period for ensuing 33rd AGM which is to be held on 30.09.2026 will commence from 27.09.2026 (09:00 a.m. IST) and ends on 29.09.2026 (05:00 p.m. IST) (Both days inclusive).
1 week agoThe E-voting period for ensuing 33rd AGM which is to be held on 30.09.2026 will commence from 27.09.2026 (09:00 a.m. IST) and ends on 29.09.2026 (05:00 p.m. IST) (Both days inclusive).
1 week agoRegister of Members and Share transfer book of the Company will remain closed from 24.09.2026 to 30.09.2026 (Both days Inclusive) for the purpose of 33rd Annual General Meeting of the Company.
1 week agoRegister of Members and Share transfer book of the Company will remain closed from 24.09.2026 to 30.09.2026 (Both days Inclusive) for the purpose of 33rd Annual General Meeting of the Company.
1 week agoRe-appointment of Mrs. Abha Agrawal (DIN: 01589479) as a Non -executive Non- Inependent Director of the Company post attaining the age of 75 years.
3 weeks agoRe-appointment of Mrs. Abha Agrawal (DIN: 01589479) as a Non -executive Non- Inependent Director of the Company post attaining the age of 75 years.
3 weeks agoUnaudited Financial Results of the Compmany for the quarter ended 30th June 2026 along with limited review report issued by statutory auditor.
3 weeks agoUnaudited Financial Results of the Compmany for the quarter ended 30th June 2026 along with limited review report issued by statutory auditor.
3 weeks agoOutcome of the Board meeting held on 08th August 2026.
3 weeks agoOutcome of the Board meeting held on 08th August 2026.
3 weeks agoIshita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2026 inter alia to consider and approve 1. To consider approve and take on record the Unaudited Financial Results of the Company for the quarter ended 30th June 2026.2. Any other matter with permission of the Chair.
1 month agoIshita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2026 inter alia to consider and approve 1. To consider approve and take on record the Unaudited Financial Results of the Company for the quarter ended 30th June 2026.2. Any other matter with permission of the Chair.
1 month agoCompliance Certificate under regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ended 30th June 2026 as attached.
1 month agoCompliance Certificate under regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ended 30th June 2026 as attached.
1 month agoThe trading window for dealing in securities of the Company by designated persons stands closed from Wednesday 1st July 2026 till 48 hours after the declaration of the Unaudited Financial Results for the quarter ended 30th June 2026 .
2 months agoThe trading window for dealing in securities of the Company by designated persons stands closed from Wednesday 1st July 2026 till 48 hours after the declaration of the Unaudited Financial Results for the quarter ended 30th June 2026 .
2 months agoDisclosure under regulation 29(2) of SEBI(SAST) Regulations 2011 received from Ishita Pharmaceuticals related party of Ishita Drugs and Industries Limited.
2 months agoDisclosure under regulation 29(2) of SEBI(SAST) Regulations 2011 received from Ishita Pharmaceuticals related party of Ishita Drugs and Industries Limited.
2 months agoDisclosure under regulation 29(2) of SEBI (SAST) Regulations 2011 received from Ishita Pharmaceuticals related party of ishita Drugs and Industries Limited.
2 months agoDisclosure under regulation 29(2) of SEBI (SAST) Regulations 2011 received from Ishita Pharmaceuticals related party of ishita Drugs and Industries Limited.
2 months agoAudited Financial Results for the quarter and year ended 31st March 2026
3 months agoAudited Financial Results for the quarter and year ended 31st March 2026
3 months agoOutcome of Board Meeting held on 30th May 2026
3 months agoOutcome of Board Meeting held on 30th May 2026
3 months agoIshita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 inter alia to consider and approve 1. To consider approve and take on records the Audited Financial Results of the Company for the quarter and year ended 31st March 2026 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. 2. To consider and approve the Directors Report with the Annexure Corporate Governance Report Management Discussion and Analysis Report and Notice for convening the 33rd Annual General Meeting of the Company.3. To consider the re-appointment of Internal Auditors of the Company for the year 2026-27.4. To take on record Disclosure of Interest of Directors.5. Any other matter with permission of the Chair.
3 months agoThe meeting of the Board of Directors of the Company will be held on Saturday 30th May 2026 to transact the following business:1. To consider and take on records the Audited Financial Results of the Company fo the quarter and year ended 31st March 2026 pursunt to regulation 33 of the SEBI (LODR) Regulations 2015.2. To consider and approve the Directors Report with Annexures and Notice for convening the 33rd AGM of the Company.3. To consider the re-appointment of internal Auditors of the Company for the year 2026-27.4. To take on record Disclosure of Interest of Directors.5. Any other matter with the permission of the chair.
3 months agoThe meeting of the Board of Directors of the Company will be held on Saturday 30th May 2026 to transact the following business:1. To consider and take on records the Audited Financial Results of the Company fo the quarter and year ended 31st March 2026 pursunt to regulation 33 of the SEBI (LODR) Regulations 2015.2. To consider and approve the Directors Report with Annexures and Notice for convening the 33rd AGM of the Company.3. To consider the re-appointment of internal Auditors of the Company for the year 2026-27.4. To take on record Disclosure of Interest of Directors.5. Any other matter with the permission of the chair.
3 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Ishita Drugs & Industries Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24231GJ1992PLC017054</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.14</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Srushti Pandya <br/> Designation: Company Secretary <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Sumit Agrawal <br/> Designation: Chief Financial Officer <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 28/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Ishita Drugs & Industries Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24231GJ1992PLC017054</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.14</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Srushti Pandya <br/> Designation: Company Secretary <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Sumit Agrawal <br/> Designation: Chief Financial Officer <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 28/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months agoNon-Applicability of Annual Secretarial Compliance Certificate for the year ended 31st March 2026
4 months agoNon-Applicability of Annual Secretarial Compliance Certificate for the year ended 31st March 2026
4 months agoNon - applicability of Regulation 32(1) of SEBI(LODR) Regulations 2015 for the year ended 31st March 2026.
4 months agoNon - applicability of Regulation 32(1) of SEBI(LODR) Regulations 2015 for the year ended 31st March 2026.
4 months agoComplaince Certificate under Regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ended 31st March 2026 as attached.
4 months agoThe trading window for dealing in securities of the Company by designated persons stands closed from Wednesday 01st April 2026 till 48 hours after the declaration of the Audited Financial Results for the quarter and Financial year ended 31st March 2026.
5 months agoThe trading window for dealing in securities of the Company by designated persons stands closed from Wednesday 01st April 2026 till 48 hours after the declaration of the Audited Financial Results for the quarter and Financial year ended 31st March 2026.
5 months agoDisclosure under regulation 29(2) of SEBI(SAST) Regulations 2011 received from Ishita Pharmaceuticals related party of Ishita Drgs and Industrie Limited.
6 months agoDisclosure under regulation 29(2) of SEBI(SAST) Regulations 2011 received from Ishita Pharmaceuticals related party of Ishita Drgs and Industrie Limited.
6 months agoDisclosure under regulation 29(2) of SEBI(SAST)Regulations 2011 received from Ishita Pharmaceuticals related party of Ishita Drugs and Industries Limited.
6 months agoDisclosure under regulation 29(2) of SEBI(SAST)Regulations 2011 received from Ishita Pharmaceuticals related party of Ishita Drugs and Industries Limited.
6 months agoDisclosure under regulation 29(2) of SEBI (SAST) Regulations 2011 received from Ishita Pharmaceuticals related party of Ishita Drugs and Industries Limited.
6 months agoDisclosure under regulation 29(2) of SEBI (SAST) Regulations 2011 received from Ishita Pharmaceuticals related party of Ishita Drugs and Industries Limited.
6 months agoDisclosure under regulation 29(2) of SEBI(SAST) Regulations 2011 received from Ishita Pharmaceuticals related party of Ishita Drugs and Industries Limited
6 months agoUnaudited Financial Results for the quarter ended 31st December 2025 along with Limited review report issued by the statutory auditors of the Company
6 months agoAnnual reports
Concalls & investor presentations
No presentations found
Corporate Actions
Date
Type
Details
No data available.
Company details
Registered office
Survey No 179 / 1 Village : Vasna - Lyava Taluka : Sanand Ahmedabad Dist Gujarat PIN: 382170 Tel No: 7226995613-15 / 079 - 40023839 Fax No: 079 - 26404961 Email: [email protected] / [email protected] Internet: www.ishitadrugs.com
Registrars
New Address : Office No. 303, Sun Square Complex , Near Chakradhari Society Bus Stop , Girish Cold Drinks Cross Road, C.G. Road, Navrangpura , Ahmedabad – 380009 Old Address : A/802, Samudra Complex, Near Klassic Gold, Girish Gold Drink, CG Road, Ahmeda Office No. 303, Sun Square Complex Near Chakradhari Society Bus Stop Girish Cold Drinks Cross Road, C.G. Road, Navrangpura PIN: Tel No: NULL Fax No: NULL Email: [email protected]
Management
Jagdish Agrawal, Managing Director
Abha Agrawal, Non Executive Director
Arvind Sapkal, Non Executive Independent Director
Dhwani Solanki, Non Executive Director
Srushti Pandya, Company Secretary & Compliance Officer
Details
BSE 524400
NSE NULL
ISIN INE806D01016